Together, the data suggest that ganetespib may serve as an effective treatment strategy for prostate cancers driven by AR, truncated forms of the receptor that confer androgen independence, as well as castrate-resistant tumors no longer reliant on the receptor itself. Here, AR is linked to prostate cancer.